All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2026-09-01

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III Relapsing Multiple Sclerosis trials

Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile. The results of the REMODEL trials establish remibrutinib

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-08-19

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with

Read More

No Comments InCANCER IMMUNOTHERAPY PRECISION MEDICINE
PIER MARIA FORNASARI
2026-08-18

Implantable device may help restore function after spinal cord injury

Ultra thin, flexible interface locates alternative signal pathways to bypass affected area Researchers from Houston Methodist and the University of Cambridge have developed a flexible device that wraps around the spinal cord and can simultaneously interpret multiple signals related to movement, sensation and internal body functions. The research demonstrates that a single device may be

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2026-08-18

Researchers find cold-stored platelets safe and effective in cardiac surgery up to 21 days

CHIP trial extends shelf life compared with conventional room-temperature storage Key Takeaways Extending the shelf life of platelets with refrigeration didn’t hurt their hemostatic function for people undergoing complex cardiac surgery, the landmark CHIPS trial found. Platelets stored at 1-6°C (33.8-42.8°F) for up to 21 days were noninferior to platelets stored up to 7 days

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-08-17

Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO new GLP 1 Consensus Statement.

The Lancet Diabetes & Endocrinology recently published a consensus piece on using GLP-1 medications for obesity in Europe. The paper, “Nutritional, Functional, and Psychological Considerations for Incretin-Based Therapies in Adults—an EASO, EFAD, and ECPO Consensus Statement“, aimed to provide guidance on best practices for clinicians prescribing obesity medications — but one could argue, it’s more likely to lead

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-29

In calcium-replete older women, calcium supplements had little effect on the response to antiresorptives, whereas low protein intake blunted their benefits. 

In older women with adequate calcium intake receiving osteoporosis medications, calcium supplements did not provide additional improvements in hip bone mineral density (BMD) or bone strength. However, a low dietary protein intake was associated with reduced skeletal benefits of antiresorptive therapy. METHODOLOGY TAKEAWAY IN PRACTICE “[The study] findings do not support the routine use of CaS [calcium

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-22

Prevention of heart failure: A scientific statement of the Heart Failure Association, the European Association of Preventive Cardiology, and the Association of Cardiovascular Nursing & Allied Professions of the ESC, and the ESC Council on Hypertension

Heart failure already affects more than 60 million people worldwide and is one of the leading causes of hospitalization among people over the age of 65. Although it is commonly associated with advanced cardiovascular disease, it actually develops over many years, often without symptoms. Authors of a new expert statement published in the European Heart

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-22

Caffeine and cardiovascular health: a new American Heart Association review

Although the relationship between caffeine and cardiovascular health is complex, the latest research indicates consuming up to 5 cups of caffeinated coffee per day (up to 400 mg of caffeine/day) is safe for most adults and may be linked to cardiovascular health benefits in some individuals, according to a new American Heart Association scientific statement.

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-21

New position statement calls for systematic bone health optimization before joint replacement and spinal fusion surgery

International expert group reframes arthroplasty and spinal fusion complications as a shared problem of implant fixation failure, and issues clinical recommendations for peri-operative bone health care. A new position statement from the International Osteoporosis Foundation’s (IOF) Committee of Scientific Advisors Fracture Working Group urges orthopaedic surgeons and bone health specialists to work together to assess and treat

Read More

No Comments InWELLNESS